Press Release

Nov 12, 2018
WAYLAND, MASSACHUSETTS, NOVEMBER 12, 2018 – Candela Corporation, a leading global aesthetic device company, announces that the ProfoundÒ treatment has been named  “New Treatment of the Year” by The Global Aesthetic Awards, a leading aesthetic industry award, also known as MyFaceMyBody Awards USA. The Profound system is the only radiofrequency (RF) microneedling device that uses real-time temperature control to yield predictable outcomes and is FDA-cleared for the treatment of facial wrinkles and improvements in the appearance of cellulite[1]. The prestigious MyFaceMyBody Awards, now... Read More
Oct 01, 2018
Syneron Candela Korea Co. Ltd focused on enhancing Customer Service in Growth Markets WAYLAND, MASSACHUSETTS, October 1, 2018 - Syneron Candela announces the opening of Syneron Candela Korea Co Ltd, a new headquarters designed to support all commercial activities for the entire Syneron Candela portfolio of products in Korea. Formally known as Syneron Candela (Korea) Medical Technologies Co Ltd, the new entity will provide Syneron Candela customers with direct support to address capital needs for their practice as well as a high level of service, technical, education, training... Read More
Sep 05, 2018
Acquisition of Danish Ellipse adds globally renowned IPL and laser technologies to Candela’s portfolio, further strengthening their position in multi-application, multi-technology devices WAYLAND, MASSACHUSETTS, September 5, 2018 – Candela Corporation, a leading global aesthetic device company, announces the acquisition of Ellipse, a Danish medical device company that manufactures and markets Intense Pulsed Light (IPL) and laser-based platforms for a wide variety of medical and aesthetic skin treatments. Financial terms of the agreement were not disclosed. “The acquisition of Ellipse... Read More
Jul 17, 2018
The new Vbeam Prima takes Candela’s “gold standard” 595 nm Pulsed Dye Laser (PDL) platform to the next level   WAYLAND, MASSACHUSETTS, JULY 17, 2018 – Candela Corporation, a leading global aesthetic device company, announces the U.S. Food and Drug Administration (FDA) clearance of its Vbeam® Prima, an advanced 595 nm pulsed dye laser (PDL). With the addition of a 1064 nm wavelength and a number of other new features, the Vbeam Prima will be able to effectively treat a broad range of skin conditions, including: rosacea, port wine stains, acne, facial, leg and spider veins, scars,... Read More
CONTACT
PATIENTS